Results 91 to 100 of about 6,882 (175)

Skillnaden i effektivitet mellan rituximab och eltrombopag för behandling av kronisk immunologisk trombocytopeni

, 2023
Introduktion: Immunologisk trombocytopeni, ITP är en autoimmun sjukdom. Hos ITP patienter bildas autoantikroppar mot trombocyter som leder till trombocyt eliminering och därmed till trombocytopeni. ITP kan delas in i olika grupper beroende på durationen.
Shakra, Rewa
core  

İmmün trombositopenik purpuralı sirozlu bir hastada eltrombopag tedavisi sırasında portal ven trombozu [PDF]

, 2016
Portal ven trombozu karaciğer sirozunda görülen nadir ancak ciddi bir komplikasyondur. Eltrombopag immün trombositopenide kullanılan ikinci jenerasyon bir ajandır. Trombotik komplikasyonlara yol açabilmektedir.
Acıpayam, Can, İlhan, Gül
core  

An Uncommon Association: Eltrombopag and Autoimmune Hepatitis

Case Reports in Hepatology
Autoimmune hepatitis (AIH) is an immunological disorder of the liver characterized by hepatic necroinflammation due to the break in self-tolerance to autoantigens. Many medications have been linked to drug induced AIH.
Fady Salama, Hassnain Syed, Nimish Thakral   +2 more
doaj   +1 more source

Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. [PDF]

Slow platelet recovery frequently occurs after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with bone marrow graft and post-transplant cyclophosphamide (PCy)-based graft-versus-host disease (GVHD) prophylaxis.
Nieto, Yago, Andersson, Borje, Ullah, Fauzia, Shpall, Elizabeth, Khouri, Issa, Bashir, Qaiser, Aung, Fleur, Mehta, Rohtesh, Marin, David, Ciurea, Stefan, Alousi, Amin, Olson, Amanda, Oran, Betul, Champlin, Richard, Hosing, Chitra, Qazilbash, Muzaffar, Popat, Uday, Ahmed, Sairah, Bassett, Roland, Kebriaei, Partow, Valdez, Benigno, Rezvani, Katayoun   +21 more
core   +1 more source

Genetic variability in thrombopoietin receptor and GATA1 influences response to eltrombopag in dengue-induced thrombocytopenia

Scientific Reports
Integrating pharmacogenetic studies into clinical trials enhances personalized medicine by identifying genetic variations that influence drug efficacy and safety.
Mohammad Sayem, Razoan Al Rimon, Saruar Alam, Abdullah Al Saba, Mousumi Sanyal, Mohammad Sayem, Chowdhury Tamanna Tabassum, Md. Robed Amin, Sajib Chakraborty, Ahmedul Kabir, A. H. M. Nurun Nabi   +10 more
doaj   +1 more source

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States

ClinicoEconomics and Outcomes Research, 2019
Gabriel Tremblay,1 Qayyim Said,2 Anuja Nidumolu Roy,2 Beilei Cai,2 Shan Ashton Garib,1 Jaclyn Hearnden,1 Anna Forsythe1 1Purple Squirrel Economics, New York, NY, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USACorrespondence: Gabriel ...
Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A   +6 more
doaj  

Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

, 2018
Gabriel Tremblay,1 Mike Dolph,1 Menaka Bhor,2 Qayyim Said,2 Brian Elliott,2 Andrew Briggs3 1Department of Health Economics, Purple Squirrel Economics, New York, NY, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals ...
Said Q, Tremblay G, Briggs A, Bhor M, Elliott B, Dolph M   +5 more
core  

Bioequivalence study of eltrombopag 75 mg film-coated tablets under fasting conditions during the Covid-19 pandemic in healthy Caucasian male subjects

• Bioequivalence of eltrombopag film-coated tablets • Safety evaluation of eltrombopag film-coated tablets This study aims to determine the bioequivalence of the reference preparation and the test preparation containing eltrombopag when both were given ...
Mazicioglu, Mumtaz M., Pinarbasli, Onur, Martin, Wolfgang, SEZER, ZAFER, Koru, Selma Alime, Bulut, Burcu, Reinsch, Martin, İNAL, AHMET, MAZICIOĞLU, MUSTAFA MÜMTAZ   +8 more
core   +1 more source

Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos 39

, 2011
: The metabolism and disposition of eltrombopag, the first-in-class small molecule human thrombopoietin receptor agonist, were studied in six healthy men after a single oral administration of a solution dose of [ 14 C]eltrombopag (75 mg, 100 Ci ...
Ernest Schubert, Peter D Gorycki, Frances Gorycki, Mark Levy, Mary Beth Wire, Jung Wook Park, Daphne Williams, Armina Madatian, Carolyn Bowen, Bin Peng, Yanli Deng   +10 more
core  

A Paradoxical Case of Bleeding and Clots: The Hidden Thrombotic Threat in Immune Thrombocytopenic Purpura. [PDF]

Clin Case Rep
Sarker NK, Das S, Alam MK, Sarker SD, Rahman MH.   +4 more
europepmc   +1 more source